Evaluation of ARO-ATXN2 Injection in Adult Patients With Spinocerebellar Ataxia Type 2

The primary objective of this study is to evaluate the efficacy and safety of **ARO-ATXN2 injection** in adults diagnosed with **spinocerebellar ataxia type 2**. This condition is a progressive neurodegenerative disorder characterized by ataxia, which significantly impacts motor coordination and balance. Understanding the therapeutic potential of ARO-ATXN2 is clinically relevant as it may offer a novel treatment option for managing symptoms and potentially altering the disease course in affected individuals.

The clinical trial involves a total of **20 participants** diagnosed with **spinocerebellar ataxia type 2**. The study population includes both male and female subjects, with an age range of 18 to 65 years. Participants were selected based on specific criteria, although the principal inclusion criteria were not provided. The trial does not focus on a vulnerable population. General health status and lifestyle considerations such as diet, physical activity, or habits were not specified by the sponsor. The selection process aimed to ensure a representative sample of individuals affected by the condition under investigation.

The clinical trial is designed to evaluate the safety and efficacy of an investigational product in adults diagnosed with **spinocerebellar ataxia type 2**. This study is structured as a Phase 1 trial, employing a randomized, double-blind, and controlled methodology to ensure the reliability and validity of the results. The trial is anticipated to commence recruitment on April 2, 2025, and is projected to conclude by December 7, 2026, encompassing a total duration of approximately 20 months.

Participants will undergo a series of study visits, beginning with an inclusion (screening) visit to assess eligibility based on predefined criteria. This initial visit will involve comprehensive evaluations to confirm the diagnosis and suitability for participation. Following successful screening, participants will be randomized into treatment groups and will attend regular follow-up visits. These visits are designed to monitor safety, collect efficacy data, and ensure adherence to the study protocol. The frequency and specific assessments conducted during these visits will be determined by the study protocol.

The end-of-study visit will mark the conclusion of the participant's involvement in the trial. This visit will include final assessments to evaluate the overall impact of the investigational product and to ensure participant safety. The expected length of participant involvement will vary depending on individual response and adherence to the study protocol, but it is generally anticipated to last until the end of the trial period. Conditions that may lead to early termination from the study include adverse events, non-compliance with study procedures, or withdrawal of consent by the participant.

No specific information regarding the experimental medication, including its name, pharmaceutical form, dosage, route, and frequency of administration, is provided in the available data. Additionally, there is no information on any non-experimental treatments, such as standard-of-care therapy, placebo, or comparator treatment, used in the study. Details about drug administration, dosing schedules, and participant compliance monitoring are also not available. Consequently, a comprehensive description of the treatments used in this clinical trial cannot be constructed based on the provided data.

The clinical trial is designed to assess efficacy through a structured evaluation process. The trial is categorized as a Phase 1 study, indicating an early stage of clinical research primarily focused on safety and dosage. The estimated recruitment start date is April 2, 2025, with an anticipated end date of December 7, 2026. Although specific efficacy parameters such as primary or secondary endpoints are not detailed, typical Phase 1 trials often involve preliminary assessments of therapeutic effects alongside safety evaluations. The trial will likely employ standardized methods for measuring and collecting data, which may include validated scales, laboratory tests, or patient-reported outcomes, depending on the investigational product and disease context. The analysis of efficacy data will be conducted in accordance with the trial's protocol, ensuring rigorous and scientifically sound conclusions. The absence of detailed endpoints suggests a focus on exploratory outcomes, which is common in early-phase trials.